Disinfection by 1% sodium hypochlorite through cold fogging: an innovative appropriate technology against COVID-19 in public health

Background: SARS-CoV-2 is an enveloped virus with a fragile outer lipid envelope that makes it more susceptible to disinfectants compared to non-enveloped viruses. In this article, dispensation through cold Fogger was innovated as a measure against aerosol-based transmission of COVID-19 in large, enclosed spaces like hospitals, nursing homes, isolation centers and quarantine facilities.Methods: Ecological exploratory study, to ours effectiveness of 1% sodium hypochlorite through cold fogging against SARS COV-2 technology. Study setting included medical college in Western Maharashtra and the selected COVID-19 hospitals. The data was collated in MS excel and analysed using IBM SPSS version 23.0.Results: Average of 2.9 % HCWs got infected in hospitals where this innovation was used to disinfect, as compared to infections rates of 21.5% and 14.7% in other premier health institutes. There was strong negative correlation between percentage of health care infected and liters of sodium hypochlorite used with R2=0.56. Also, on applying Spearman correlation coefficient there was good negative correlation (-0.8).Conclusions: This appropriate technology has shown significant reduction in infection, with antecedent benefit of decreased morbidity and mortality of precious trained manpower. It gives much better dis-infection at 07 times less the cost and can be conveniently used for dis-infection against COVID-19 at the very periphery of primary health care delivery done at Sub-centres and PHCs

Review on various Pharmaceuticals and their Pharmacology of Anti-repellents- As a Preventive aspect of Vector (mosquito species) borne Disease

Mosquito is one of the most vexing bloodsucking insects. Malaria, Filariasis, Japanese Encephalitis, Dengue fever, Yellow fever, Chikungunya, and Zika are all transmitted by mosquito species belonging to the genera Anopheles, Culex, & Aedes. Mosquitoes alone infect almost 700 million people each year, resulting in one million fatalities. Malaria, which is caused by Plasmodium parasites and transmitted by female Anopheles mosquito bites, is still a substantial illness that impacts the development of infants and kids. Present review work aims to review various pharmaceutical dosage forms of anti-repellent products and their molecules, mechanism of repellent activity as a preventive of different vector bone diseases. Malaria cases were over 207 million in 2012, with 627,000 deaths reported. In addition, Yellow fever, which is spread by the Haematologus and Aedes mosquitoes, causes 200,000 instances of disease and 30,000 fatalities worldwide each year. Dengue fever is spread by Aedes aegypti and Aedes albopictus mosquitos, which are responsible for more than 100 million infections yearly. Furthermore, more than 2.5 billion individuals, or about 40% of the world's population, are now in danger of contracting Dengue fever. This review helped to understand the various kinds of vector bone disease and the surveillance of disease data. In addition, the review revealed the various pharmaceutical products would help control the Mosquitoes bits and related disease as preventive aspects and the components of pharmaceutical and their mechanism of action to inhibit the spread of various insects’ related disease

Awareness, perceptions, and attitude towards Coronavirus disease 2019 vaccine among pregnant women in India: A cross-sectional study

Introduction: The present study was conducted to explore the awareness and perception of the coronavirus disease 2019 (COVID-19) vaccine among pregnant women. Material and Methods: A descriptive cross-sectional study was conducted from September 01, 2021, to September 28, 2021, among 301 pregnant women aged 18–35 years at antenatal care outpatient department in a tertiary care hospital of Western Maharashtra. Results: On assessing the knowledge and awareness score, the mean score (± standard deviation) was 7.83 ± 1.2 out of 16. A total of 176 (58.5%) had good scores (≥8). There was no statistically significant association between knowledge and awareness scores and the level of education, type of residence, and age or with weeks of gestation. Although the overall awareness of study participants was satisfactory, 177 (58.8%) felt that COVID-19 vaccines should be avoided during the first trimester. Interestingly, 45 (15.3%) felt that vaccines should not be given during menstruation. There were misconceptions about perceived contraindication, with 81(26.9%), 50(16.6%) and 43(14.4%) responding that diabetes, hypertension and heart disease are contradicts respectively. Interestingly, a total of 52 (17.3%) responded as likely when enquired whether the present vaccine can cause infertility. Similarly, about 62% of study participants felt that the vaccine might alter the DNA. Conclusion: The present study revealed good overall knowledge and awareness about the COVID-19 vaccine among pregnant with certain misconceptions. The findings suggest that immediate health education programs, risk communication, and correct information should be disseminated by respective health authorities

Corbevax vaccine side effects in children of age group 12–14 years: A prospective observational study

Introduction: Corbevax was introduced by the Government of India in March 2022 for the vaccination of children between 12 and 14 years, however, there is a dearth of literature providing side effect profiles of Corbevax in the real-world/community. Hence, this study was conducted to assess the incidence and types of adverse events following immunization (AEFI) of Corbevax vaccine. Materials and Methods: A prospective observational study was conducted among 358 children between 12 and 14 years of age who had received Corbevax vaccine at a tertiary care center in western Maharashtra from March 16 to May 31, 2022. The participants were followed-up telephonically for side effects at 24 h, 72 h, and 7 days following the first dose and second doses of vaccinations. Results: Out of 358 children of age 12–14 years who received Corbevax vaccine, almost 80% of vaccines developed mild AEFI. Overall, reactogenicity was higher after the second dose and the most common AEFI was pain in the abdomen, followed by headache and pain at the site of injection. Occurrence of AEFI after the first dose (odds ratio: 158.87, 95% confidence interval 46.58–528.28, P < 0.005) was found to be a risk factor for the development of AEFI after the second dose. Conclusion: Corbevax was introduced in India for children between 12 and 14 years, but to the best of our knowledge, till date, there is no study specifically focused of AEFI due to Corbevax in the community setting. The study findings indicate that Corbevax is a safe vaccine with few mild side effects, thus reinforcing faith in the safety profile of the vaccine